Becton Dickinson reports positive trial results for Revello stent

By Kelly Cloonan Becton Dickinson said a device aimed at treating iliac artery disease met the primary composite endpoint in a recent trial. The medical-device maker said Wednesday that treatment with its Revello Vascular Covered Stent at nine months met a composite safety and effectiveness endpoint with a failure rate of 2.8%, below the 19% goal set ahead of time. Patients experienced gains in daily function and mobility, the company said. The company said the results support the continued evaluation of the device. Clinical follow-up for the study's iliac cohort is ongoing through 36 months, the company said. Write to Kelly Cloonan at kelly.cloonan@wsj.com (END) Dow Jones Newswires October 07, 2026 08:45 ET (12:45 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.